Old API Wind-down Ltd.
ARLZ evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ARLZ—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2018.
Tracking 1 pipeline candidate for Old API Wind-down Ltd..
Run Old API Wind-down Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Old API Wind-down Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
Profitable (positive operating cash flow)
OCF $19M · Net income -$20M · Debt/OCF 3.1×
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is Old API Wind-down Ltd.'s lead drug candidate?
Old API Wind-down Ltd.'s most advanced tracked candidate is treximet (Approved) for acute treatment of migraine attacks.
Who is the CEO of Old API Wind-down Ltd.?
Adrian Adams is the chief executive officer of Old API Wind-down Ltd. (ARLZ).
What therapeutic areas does Old API Wind-down Ltd. focus on?
Old API Wind-down Ltd. develops therapies across Neurology, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.